atenolol has been researched along with Arteriosclerosis, Coronary in 28 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore possible differential effects between metoprolol and atenolol in patients with coronary artery disease." | 9.16 | Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease. ( Aaberge, L; Ablad, B; Bjurö, T; Gullestad, L; Høglund, L; Kjekshus, E; Mellgård, AJ; Pernow, J; Skårdal, R; Wahlquist, I, 2012) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 9.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "We hypothesized that nebivolol, a β-blocker with nitric oxide-mediated activity, compared with atenolol, a β-blocker without such activity, would decrease oxidative stress and improve the effects of endothelial dysfunction and wall shear stress (WSS), thereby reducing atherosclerosis progression and vulnerability in patients with nonobstructive coronary artery disease." | 5.22 | Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary ( Ahn, SG; Corban, MT; Dhawan, S; Eshtehardi, P; Giddens, DP; Gogas, BD; Hung, OY; Maynard, C; McDaniel, MC; Molony, D; Piccinelli, M; Quyyumi, AA; Rasoul-Arzrumly, E; Samady, H; Timmins, LH, 2016) |
| "To explore possible differential effects between metoprolol and atenolol in patients with coronary artery disease." | 5.16 | Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease. ( Aaberge, L; Ablad, B; Bjurö, T; Gullestad, L; Høglund, L; Kjekshus, E; Mellgård, AJ; Pernow, J; Skårdal, R; Wahlquist, I, 2012) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| "When antihypertensive treatment options are clinically equivalent, prescribers may first consider using a verapamil SR-based strategy, especially in patients with CAD who have no history of depression." | 5.12 | Depressive symptoms in coronary artery disease patients after hypertension treatment. ( Lopez, LM; Pepine, CJ; Ried, LD; Sauer, BC; Taylor, MD; Tueth, MJ, 2006) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 5.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| " Metabolic dysregulation is a major contributor to coronary disease; therefore, we assessed LXRA in International Verapamil Sustained Release SR Trandolapril Study Genetic Substudy (INVEST-GENES), a genetic-substudy of a large clinical trial in patients with hypertension and coronary artery disease." | 3.77 | Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. ( Cooper-DeHoff, RM; Johnson, JA; Martin, MA; Pacanowski, MA; Pepine, CJ; Price, ET; Zineh, I, 2011) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 20 (71.43) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Dasa, O | 1 |
| Smith, SM | 1 |
| Howard, G | 1 |
| Cooper-DeHoff, RM | 12 |
| Gong, Y | 4 |
| Handberg, E | 2 |
| Pepine, CJ | 17 |
| Denardo, SJ | 1 |
| Farsang, C | 1 |
| Keltai, M | 2 |
| Szirmai, L | 1 |
| Messerli, FH | 8 |
| Bavry, AA | 1 |
| Handberg, EM | 4 |
| Mancia, G | 7 |
| Hung, OY | 1 |
| Molony, D | 1 |
| Corban, MT | 1 |
| Rasoul-Arzrumly, E | 1 |
| Maynard, C | 1 |
| Eshtehardi, P | 1 |
| Dhawan, S | 1 |
| Timmins, LH | 1 |
| Piccinelli, M | 1 |
| Ahn, SG | 1 |
| Gogas, BD | 1 |
| McDaniel, MC | 1 |
| Quyyumi, AA | 1 |
| Giddens, DP | 1 |
| Samady, H | 1 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Bangalore, S | 2 |
| Franklin, SS | 1 |
| Champion, A | 6 |
| Pacanowski, MA | 2 |
| Zineh, I | 2 |
| Johnson, JA | 4 |
| Gerhard, T | 1 |
| Ried, LD | 2 |
| Bakris, GL | 4 |
| Zhou, Q | 4 |
| Kupfer, S | 4 |
| Legler, UF | 1 |
| Weber, MA | 1 |
| Price, ET | 1 |
| Martin, MA | 1 |
| Gullestad, L | 1 |
| Pernow, J | 1 |
| Bjurö, T | 1 |
| Aaberge, L | 1 |
| Skårdal, R | 1 |
| Kjekshus, E | 1 |
| Høglund, L | 1 |
| Mellgård, AJ | 1 |
| Wahlquist, I | 1 |
| Ablad, B | 1 |
| Vandell, AG | 1 |
| Lobmeyer, MT | 1 |
| Gawronski, BE | 1 |
| Langaee, TY | 1 |
| Gums, JG | 1 |
| Beitelshees, AL | 1 |
| Turner, ST | 1 |
| Chapman, AB | 1 |
| Bailey, KR | 1 |
| Boerwinkle, E | 1 |
| Liggett, SB | 1 |
| Hanania, G | 1 |
| Haïat, R | 1 |
| Olive, T | 1 |
| Maalouf, B | 1 |
| Michel, D | 1 |
| Martelet, M | 1 |
| Godard, S | 1 |
| Donaldson, KM | 1 |
| Dawkins, KD | 1 |
| Waller, DG | 1 |
| Merritt, JC | 1 |
| Niebauer, M | 1 |
| Tarakji, K | 1 |
| Hammer, D | 1 |
| Mills, RM | 1 |
| Marks, RG | 1 |
| Kowey, P | 1 |
| Cangiano, JL | 1 |
| Garcia-Barreto, D | 1 |
| Erdine, S | 3 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Cohen, JD | 2 |
| Parmley, WW | 1 |
| Gaxiola, E | 2 |
| Cooper-DeHoff, R | 2 |
| Huffman, JC | 1 |
| Wulsin, LR | 1 |
| Stern, TA | 1 |
| Lekakis, JP | 1 |
| Protogerou, A | 1 |
| Papamichael, C | 1 |
| Vamvakou, G | 1 |
| Ikonomidis, I | 1 |
| Iconomidis, I | 1 |
| Fici, F | 1 |
| Mavrikakis, M | 1 |
| Kowey, PR | 1 |
| Kolloch, RE | 1 |
| Benetos, A | 3 |
| Coca, A | 2 |
| Sleight, P | 1 |
| Conti, CR | 2 |
| Hewkin, AC | 3 |
| Tavazzi, L | 1 |
| Tueth, MJ | 1 |
| Taylor, MD | 1 |
| Sauer, BC | 1 |
| Lopez, LM | 1 |
| Kolloch, R | 1 |
| Uretsky, S | 1 |
| Sagiv, M | 1 |
| Ben-Sira, D | 1 |
| Goldhammer, E | 1 |
| Kuster, GM | 1 |
| Amann, FW | 1 |
| Neuenschwander, C | 1 |
| Drexel, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease[NCT01230892] | Phase 4 | 29 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS) (NCT01230892)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 4 |
| Atenolol | 6 |
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
17 trials available for atenolol and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2015 |
Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Biomarkers; Coron | 2016 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2009 |
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2009 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Angina, Stable; Atenolol; Blood Pressure; Coron | 2012 |
[Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Coronary Artery Disease; Drug Therapy, Combination; Exe | 2002 |
A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Calcium Channel | 1993 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Brachial Artery; Coronary Artery Disease; | 2005 |
Depressive symptoms in coronary artery disease patients after hypertension treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Coronary Artery Disease; Depression; Female; Humans; Male; | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
Beta-blockers, exercise, and the immune system in men with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; CD4-CD8 Ratio; Coronary Artery Disease; Exercise; Huma | 2002 |
High density-lipoprotein subfractions of patients using cardio-selective beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apolipoproteins; Atenolol; Cholesterol; Cholesterol, HDL; | 2002 |
11 other studies available for atenolol and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease | 2010 |
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Topics: Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Case-Control Stu | 2011 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary | 2003 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
Newly diagnosed hypertension and depressive symptoms: how would you treat?
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Antihypertensive Agents; Atenolol; Coronary Arte | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |